Table 1.
Patient and OCM characteristics
| Patient | Anatomical site | Histology | FIGO stage | gBRCAm | Lines of CTx† | OCM | Seeding density (96-well) | References |
|---|---|---|---|---|---|---|---|---|
| 33 | PP | HGSOC | 4B | Unknown | 2 | 33–2 | 2000 | Nelson et al., Barnes et al., Coulson-Gilmer et al. |
| 38 | OV/PP | HGSOC | 3C | Unknown | 0 | 38 | 2000 | Nelson et al., Barnes et al. |
| 46 | OV/PP | HGSOC | 3C | Unknown | 1 | 46–3 | 1000 | Nelson et al., Barnes et al., Coulson-Gilmer et al. |
| 59 | OV/PP | HGSOC | 3C | Unknown | 2 | 59–3 | 4000 | Nelson et al., Barnes et al., Coulson-Gilmer et al. |
| 64 | OV/PP | Possible HGSOC/LGSOC mix* | 3C | Unknown | 2 | 64–1 | 1000 | Nelson et al., Barnes et al., Coulson-Gilmer et al.§ |
| 3 | 64–3- | 2000 | ||||||
| 66 | OV/PP | HGSOC | 3C | Unknown | 1 | 66–1 | 2000 | Nelson et al., Barnes et al., Coulson-Gilmer et al.§ |
| 1 | 66–5 | 3000 | ||||||
| 72 | OV | Moderately differentiated MUC | 1A | Unknown | 1 | 72 | 2000 | Nelson et al., Barnes et al. |
| 79 | OV | HGSOC | 3C | Unknown | 3 | 79 | 2000‡ | Nelson et al., Barnes et al. |
| 87 | OV | Possible CCOC* | 3B | Unknown | 0 | 87 | 1000 | Nelson et al., Barnes et al., Coulson-Gilmer et al. |
| 105 | OV/PP | HGSOC | 3C | BRCA1 VUS | 3 | 105 | 1000 | Coulson-Gilmer et al. |
| 109 | OV | HGSOC | 4B | Unknown | 3 | 109 | 5000 | Barnes et al., Coulson-Gilmer et al. |
| 152 | OV | Moderately differentiated serous adenocarcinoma of intermediate grade* | 3C | Unknown | 5 | 152 | 4000 | Barnes et al., Coulson-Gilmer et al. |
| 191 | OV | HGSOC | 3A | BRCA1 | 2 | 191 | 4000 | Barnes et al., Coulson-Gilmer et al. |
| 195 | PP | Possible LGSOC* | 4A | Unknown | 0 | 195 | 4000 | Barnes et al., Coulson-Gilmer et al. |
*See Barnes et al., 2021; †at time of research biopsy; ‡150000, 500, 2000, 4000 for 6-well, 12-well (colony formation assay), 24-well (time-lapse), coverslips, respectively; §Coulson-Gilmer et al., only included 64-1 and 66-1 (and not subsequent OCMs from these patients). CCOC, clear cell ovarian cancer; CTx=chemotherapy; gBRCAm=patient germline BRCA1/2 mutation; HGSOC=high-grade serous ovarian cancer; LGSOC=low-grade serous ovarian cancer; MOC=mucinous ovarian cancer; OV=ovary; PP=primary peritoneum; VUS, variant of uncertain clinical significance.
Note that the culture established from the third biopsy from patient 64 was further separated into EpCAM-negative (64-3-) and EpCAM-positive cells, with only OCM.64-3- included in the current analysis. See also Supplementary Figure S1.